Iovance Biotherapeutics, Inc. IOVA Share Based Compensations
Share Based Compensations at other companies
Other financials
Where this comes from
Reported directly by Iovance Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept iova:ShareBasedCompensations.
The official record: Iovance Biotherapeutics, Inc.’s 10-K, filed February 24, 2026, on SEC EDGAR. View the filing →
Ask your AI about Iovance Biotherapeutics, Inc.'s share based compensations.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Iovance Biotherapeutics, Inc.'s share based compensations?
- Iovance Biotherapeutics, Inc. (IOVA) reported share based compensations of $15.39M in Q4 2025.
- How has Iovance Biotherapeutics, Inc.'s share based compensations changed year-over-year?
- Iovance Biotherapeutics, Inc.'s share based compensations decreased by 43.8% year-over-year, from $27.41M to $15.39M.
- What is the long-term trend for Iovance Biotherapeutics, Inc.'s share based compensations?
- Over 2 years (2023 to 2025), Iovance Biotherapeutics, Inc.'s share based compensations has grown at a -0.8% compound annual growth rate (CAGR), from $62.63M to $61.58M.
- What does share based compensations mean?
- This metric aggregates the total non-cash expense recognized for all share-based payment arrangements, including stock options and restricted stock units, across the entire organization. It provides a comprehensive view of the dilution impact and total compensation cost associated with equity-based incentives. Investors use this to evaluate management's approach to talent retention and long-term incentive alignment.